• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Boston Heart Enables Healthcare Providers to Better Identify Near-Term Risk of Heart Attack or Stroke with Launch of an Important Inflammation Marker, Myeloperoxidase (MPO)
A significant addition that complements the company's innovative suite of diagnostics and services, Boston Heart's MPO is easy for clinicians to use and FDA-cleared. FRAMINGHAM, Mass., March 6, 2014 -- (Healthcare Sales & Marketing Network) -- Boston H... Diagnostics, Cardiology, Product LaunchBoston Heart Diagnostics, myeloperoxidase, MPO test, heart attack
Source: HSMN NewsFeed - March 6, 2014 Category: Pharmaceuticals Source Type: news

New Study Shows Prevencio’s Simple Blood Test Determines Risk of Heart Attack, Stroke, or Cardiovascular Death
KIRKLAND, Wash.--(Healthcare Sales & Marketing Network)--Prevencio, Inc. today announces the presentation of data which demonstrate that a simple blood test is more accurate than commonly-used risk factors in determining whether a person will have a heart ... Diagnostics, Cardiology Prevencio, HART CVE, HART CAD
Source: HSMN NewsFeed - March 17, 2017 Category: Pharmaceuticals Source Type: news

Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues
Repatha Significantly Reduces Risk of Hard Major Adverse Cardiovascular Events by 20 Percent Risks of Heart Attack, Stroke and Coronary Revascularization Were Nominally Reduced by 27 Percent, 21 Percent and 22 Percent, Respectively Patients in Study ... Biopharmaceuticals, Cardiology Amgen, Repatha, evolocumab, FOURIER trial
Source: HSMN NewsFeed - March 20, 2017 Category: Pharmaceuticals Source Type: news

Amgen Receives Positive CHMP Opinion Recognizing That Repatha(R) (evolocumab) Prevents Heart Attacks And Strokes
Recommended Label Includes New Indication Based on the Repatha Cardiovascular Outcomes Study (FOURIER) Amgen Continues to Work Closely With Payers on a Country-by-Country Basis to Ensure Access to Repatha for High-Risk Cardiovascular Patients THOUSAN... Biopharmaceuticals, Cardiology, Regulatory Amgen, Repatha, evolocumab, myocardial infarction, stroke
Source: HSMN NewsFeed - March 23, 2018 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves INVOKANA(R) (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
INVOKANA® is now the only oral diabetes treatment approved to reduce the risk of these cardiovascular events Approval aligns with ADA and AACE treatment guidance and supports use of INVOKANA® across a broad range of patients TITUSVILLE, N.J.,... Biopharmaceuticals, Endocrinology, Cardiology, FDA Janssen Pharmaceutical, INVOKANA, canagliflozin, diabetes
Source: HSMN NewsFeed - October 30, 2018 Category: Pharmaceuticals Source Type: news